Financial Security Advisor »

Edwards Lifesciences shares owned by Financial Security Advisor

Quarter-by-quarter ownership of Edwards Lifesciences (EW) shares owned by Financial Security Advisor from 13F filings

Historical chart of Financial Security Advisor investment in Edwards Lifesciences

Tip: Access up to 7 years of quarterly data

All positions including Edwards Lifesciences held by Financial Security Advisor consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Edwards Lifesciences by Financial Security Advisor

Quarter filed Position value Share count Share price at filing
2024-03-31 $266k 2.8k 95.56
2023-12-31 $212k 2.8k 76.25

More positions owned by Financial Security Advisor

Capital Group Growth ETF Exchange Traded Fund (CGGR)
Invesco S&P 500 Pure Growth ETF Exchange Traded Fund (RPG)
SPDR Portfolio S&P 600 Sm Cap ETF Exchange Traded Fund (SPSM)
Berkshire Hathaway Inc Cl B Common Stock (BRK.B)
Wisdomtree Floating Rate Treasury Fund Exchange Traded Fund (USFR)
Microsoft Corp Common Stock (MSFT)
Apple Common Stock (AAPL)
JPMorgan Ultra-Short Income ETF Exchange Traded Fund (JPST)
Johnson & Johnson Common Stock (JNJ)
SPDR S&P 600 Small Cap Growth ETF Exchange Traded Fund (SLYG)
Alphabet Inc Cl A Common Stock (GOOGL)
Exxon Mobil Corp Common Stock (XOM)
McDonalds Corp Common Stock (MCD)
Cisco Systems Common Stock (CSCO)
SPDR Portfolio S&P 500 ETF Exchange Traded Fund (SPLG)

View all positions for Financial Security Advisor

Top funds holding Edwards Lifesciences

Vanguard Group
Alliancebernstein
Bank of New York Mellon
Wellington Management Company
Brown Advisory Holdings Incorporated
Norges Bank Investment Management
Jpmorgan Chase & Co
Fisher Investments
Amundi
Henderson Group
Legal & General Group
T. Rowe Price Associates
Wellcome Trust Limited, as Trustee of the Wellcome Trust
Ubs Global Asset Management Americas
Deutsche Bank Aktiengesellschaft

View all funds holding Edwards Lifesciences